Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination

A. Hastie, G. Catteau, A. Enemuo, T. Mrkvan, B. Salaun, S. Volpe, J. Smetana, L. Rombo, T. Schwarz, K. Pauksens, C. Hervé, A. Bastidas, A. Schuind

. 2021 ; 224 (12) : 2025-2034. [pub] 20211215

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011691

BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV) is highly immunogenic and efficacious in adults ≥50 years of age. We evaluated (1) long-term immunogenicity of an initial 2-dose RZV schedule, by following up adults vaccinated at ≥60 years of age and by modeling, and (2) immunogenicity of 2 additional doses administered 10 years after initial vaccination. METHODS: Persistence of humoral and cell-mediated immune (CMI) responses to 2 initial RZV doses was assessed through 10 years after initial vaccination, and modeled through 20 years using a Piecewise, Power law and Fraser model. The immunogenicity and safety of 2 additional RZV doses were also evaluated. RESULTS: Seventy adults were enrolled. Ten years after initial vaccination, humoral and CMI responses were approximately 6-fold and 3.5-fold, respectively, above those before the initial vaccination levels. Predicted immune persistence through 20 years after initial vaccination was similar across the 3 models. Sixty-two participants (mean age [standard deviation], 82.6 [4.4] years) received ≥1 additional RZV dose. Strong anamnestic humoral and CMI responses were elicited by 1 additional dose, without further increases after a second additional dose. CONCLUSIONS: Immune responses to an initial 2-dose RZV course persisted for many years in older adults. Strong anamnestic immune responses can be induced by additional dosing 10 years after the initial 2-dose course. CLINICAL TRIALS REGISTRATION: NCT02735915.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011691
003      
CZ-PrNML
005      
20220506130027.0
007      
ta
008      
220425s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/infdis/jiaa300 $2 doi
035    __
$a (PubMed)32502272
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hastie, Andrew $u GSK, Rockville, Maryland, USA
245    10
$a Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination / $c A. Hastie, G. Catteau, A. Enemuo, T. Mrkvan, B. Salaun, S. Volpe, J. Smetana, L. Rombo, T. Schwarz, K. Pauksens, C. Hervé, A. Bastidas, A. Schuind
520    9_
$a BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV) is highly immunogenic and efficacious in adults ≥50 years of age. We evaluated (1) long-term immunogenicity of an initial 2-dose RZV schedule, by following up adults vaccinated at ≥60 years of age and by modeling, and (2) immunogenicity of 2 additional doses administered 10 years after initial vaccination. METHODS: Persistence of humoral and cell-mediated immune (CMI) responses to 2 initial RZV doses was assessed through 10 years after initial vaccination, and modeled through 20 years using a Piecewise, Power law and Fraser model. The immunogenicity and safety of 2 additional RZV doses were also evaluated. RESULTS: Seventy adults were enrolled. Ten years after initial vaccination, humoral and CMI responses were approximately 6-fold and 3.5-fold, respectively, above those before the initial vaccination levels. Predicted immune persistence through 20 years after initial vaccination was similar across the 3 models. Sixty-two participants (mean age [standard deviation], 82.6 [4.4] years) received ≥1 additional RZV dose. Strong anamnestic humoral and CMI responses were elicited by 1 additional dose, without further increases after a second additional dose. CONCLUSIONS: Immune responses to an initial 2-dose RZV course persisted for many years in older adults. Strong anamnestic immune responses can be induced by additional dosing 10 years after the initial 2-dose course. CLINICAL TRIALS REGISTRATION: NCT02735915.
650    _2
$a adjuvancia imunologická $x aplikace a dávkování $x škodlivé účinky $7 D000276
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a herpes zoster $x prevence a kontrola $7 D006562
650    _2
$a vakcína proti pásovému oparu $x aplikace a dávkování $x škodlivé účinky $7 D053061
650    _2
$a virus varicella zoster $x imunologie $7 D014645
650    _2
$a lidé $7 D006801
650    12
$a imunogenicita vakcíny $7 D000071497
650    _2
$a lidé středního věku $7 D008875
650    _2
$a vakcinace $7 D014611
650    _2
$a syntetické vakcíny $x aplikace a dávkování $x škodlivé účinky $x imunologie $7 D014614
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Catteau, Grégory $u GSK, Wavre, Belgium
700    1_
$a Enemuo, Adaora $u GSK, Rockville, Maryland, USA
700    1_
$a Mrkvan, Tomas $u GSK, Wavre, Belgium
700    1_
$a Salaun, Bruno $u GSK, Rixensart, Belgium
700    1_
$a Volpe, Stephanie $u GSK, Wavre, Belgium
700    1_
$a Smetana, Jan $u Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic
700    1_
$a Rombo, Lars $u Centre for Clinical Research, Eskilstuna, Sweden $u Uppsala University, Sweden
700    1_
$a Schwarz, Tino $u Klinikum Wuerzburg Mitte, Standort Juliusspital, Wuerzburg, Germany
700    1_
$a Pauksens, Karlis $u Department of Infectious Diseases, Uppsala University Hospital, Uppsala, Sweden
700    1_
$a Hervé, Caroline $u UCB Pharma, Braine-L'Alleud, Belgium
700    1_
$a Bastidas, Adriana $u Mithra Pharmaceuticals, Flémalle, Belgium
700    1_
$a Schuind, Anne $u GSK, Rockville, Maryland, USA
773    0_
$w MED00002745 $t The Journal of infectious diseases $x 1537-6613 $g Roč. 224, č. 12 (2021), s. 2025-2034
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32502272 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130020 $b ABA008
999    __
$a ok $b bmc $g 1789337 $s 1162889
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 224 $c 12 $d 2025-2034 $e 20211215 $i 1537-6613 $m The Journal of infectious diseases $n J Infect Dis $x MED00002745
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace